News Headlines Article

East Bay drug maker grabs $586M deal, clearing path for bigger generics pact
San Francisco Business Times

Impax Laboratories Inc. reached a deal Tuesday with Teva Pharmaceutical Industries and affiliates of Allergan to buy a broad portfolio of generic products for a total price of $586 million.

The sale, covering products from Teva and Allerga, was required by the Federal Trade Commission as a condition to the agency approving Teva’s proposed $40.5 billion acquisition of Allergan’s worldwide generics business.